Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

BACKGROUND: On August 14, 2014, the United States Food and Drug Administration approved the anti-angiogenesis drug, bevacizumab, for women with advanced cervical cancer based on a 2012 interim analysis of 271 deaths on GOG protocol 240. We now report the planned protocol-specified final analysis of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet
Main Authors: Tewari, Krishnansu S., Sill, Michael W., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., DiSaia, Philip J., Copeland, Larry J., Creasman, William T., Stehman, Frederick B., Brady, Mark F., Burger, Robert A., Thigpen, J. Tate, Birrer, Michael J., Waggoner, Steven E., Moore, David H., Look, Katherine Y., Koh, Wui-Jin, Monk, Bradley J.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5714293/
https://ncbi.nlm.nih.gov/pubmed/28756902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)31607-0
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker